2 October 2020
An interim clinical commissioning policy has been in place across the UK since 3 July 2020, defining routine access to remdesivir in the treatment of COVID-19 in adults and children aged 12 years or older. However, due to increased demand against available supply, clinicians are now asked to apply t...
9 September 2020
Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.
14 July 2020
The UK must prepare now for a potential new wave of coronavirus infections this winter that could be more serious than the first, says a new report from the Academy of Medical Sciences. Responding to 'Preparing for a challenging winter', the RCPCH made the following statement on vaccinations and pro...
26 June 2020
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.
1 May 2020
Leading paediatricians in the UK have set out a working definition of an inflammatory syndrome affecting a very small number of children and which may be associated with COVID-19.
27 April 2020
Following reports of a small number of cases of a COVID-19 related condition emerging in children, our President has made a statement.
1 April 2020
The British Paediatric Surveillance Unit has now started collecting data on neonatal complications of coronavirus disease (COVID-19) in the UK and Northern Ireland. This study is needed to understand the impact of Coronavirus infection in newborn babies and babies born to mothers with Coronavirus, s...
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
13 March 2020
Russell updates members on how the College is responding to COVID-19. In this message, which has been emailed to all members, he outlines the College's actions towards COVID-19 and highlights advice and guidance for our members.
2 March 2020
The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.